Table 2

Crude and adjusted HRs for the association between the use of glyburide and the risk of cancer

ExposureEventsPerson-yearsIncidence rate (95% CI)aCrude HRAdjusted HR (95% CI)b
Other second-generation sulfonylureas3,650250,21914.6 (14.1–15.1)1.001.00 (reference)
Glyburide45530,06915.1 (13.8–16.6)1.031.09 (0.98–1.22)
Duration of glyburide use (months)
 <121219,10013.3 (11.0–15.9)0.900.98 (0.81–1.19)
 12–24735,73912.7 (10.0–16.0)0.870.92 (0.72–1.18)
 24–36704,04117.3 (13.5–21.9)1.201.26 (0.98–1.63)
 >3619111,18917.1 (14.7–19.7)1.141.21 (1.03–1.42)
Dosage of glyburide use (DDD)
 <36516912,25313.8 (11.8–16.0)0.941.00 (0.85–1.18)
 365–730745,08614.5 (11.4–18.3)0.981.03 (0.80–1.31)
 730–1,096503,36414.9 (11.0–19.6)0.991.07 (0.80–1.44)
 >1,0961629,36717.3 (14.7–20.2)1.171.27 (1.06–1.51)
  • aPer 1,000 person-years.

  • bAdjusted for variables listed in Table 1 and for the use of antidiabetic drugs (metformin, thiazolidinediones, incretin-based drugs, insulin, and other oral hypoglycemic drugs) during follow-up as non–mutually exclusive time-dependent variables.